Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29683246 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ACA1CA2 | |
| SCHEMBL18755297 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ACA1CA2 | |
| SCHEMBL30216059 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ACA1CA2 | |
| SCHEMBL3876475 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ACA1CA2 | |
| SCHEMBL15594109 | 0.77 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2ACA1CA2 | |
| SCHEMBL29179082 | 0.77 | CA1 (0.44) | ALDH1A1MEN1KMT2ACA1CA2 | |
| SCHEMBL15000245 | 0.77 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2ACA1CA2 | |
| SCHEMBL4318211 | 0.77 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2ACA1CA2 | |
| SCHEMBL14999872 | 0.77 | MEN1 (0.44) | ALDH1A1MEN1KMT2ACA1CA2 | |
| SCHEMBL13043443 | 0.77 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498693-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| CN-109790122-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-3498693-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20140058129-A1 | Phenylacetic Acid Derivatives | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-8586782-B2 | Phenylacetic acid derivatives | NOVARTIS AG (CH) | 2013-11-19 | — | — | US | disclosed |
| US-8362294-B2 | Phenylacetic acid derivatives | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20130012585-A1 | Phenylacetic Acid Derivatives | MONOVICH LAUREN G (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2046723-B1 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | NOVARTIS AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20090209648-A1 | Phenylacetic Acid Derivatives | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| CN-101479231-A | Phenylacetic acid derivatives as COX-2 inhibitors | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| EP-0126419-A1 | 2-Substituted phenyl-4,5,6,7-tetrahydro-2H-isoindole-1,3-diones, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058129-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, GOT2 | ALDH1A1 37/4885MEN1 4496/4885KMT2A 1390/4885 |
| US-10696651-B2 | Heterocyclic compound | EIF2AK4, GCN1, GTF2I | ALDH1A1 3548/4885MEN1 415/4885KMT2A 2091/4885 |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | EIF2AK4, GCN1, GTF2I | ALDH1A1 3548/4885MEN1 415/4885KMT2A 2091/4885 |
| US-20130012585-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, GOT2 | ALDH1A1 37/4885MEN1 4496/4885KMT2A 1390/4885 |
| US-20090209648-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, PTGER2 | ALDH1A1 36/4885MEN1 4542/4885KMT2A 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.